Elizabeth Rajasingh's blog

Seminars on Drug Pricing: Part 5 Kevin Outterson, Antibiotic Delinkage

UPDATED:
Here is a link to the recording of the seminar. Please see Professor Outterson's slideshow for more detail and explanation.


Original

Seminars on Drug Pricing: Part 4, Bhaven Sampat

UPDATED:
Here is a link to the recording of the seminar. Please see Bhaven's slideshow for more detail and explanation.


Original

Commentary on TPP IP Chapter Leak

Press Releases and Articles about the IP Chapter of the TPP

Leaked text can be found here.

Some KEI Tweets regarding TPP IP Chapter

On 9 October 2015, Wikileaks released the final text of the IP chapter in the Trans-Pacific Partnership. Jamie Love provided comments via twitter.

https://twitter.com/jamie_love

Updated: 9 October 2015
(In the order posted)

Seminars on Drug Pricing: Part 3, Aidan Hollis

UPDATED:
Here is a link to the recording of the seminar. Please see Aidan's paper and slideshow for more detail and explanation.



Original

The Winning Bet

Leading up to the release of Professor Joe DiMasi's latest study of the cost of drug development, KEI offered $50 to the individual who could most accurately predict the new cost for drug R&D.

We received 26 guesses, ranging from $1.157 billion to $5 billion.

Joel Lexchin's estimate ($2.47 billion) was the closest to DiMasi's number ($2.558 billion). It was also the 5th largest estimate.

A complete list of submissions is below.

Name & Guess
Charles Clift - 1.157 billion
Nicole H - 1.2 billion
Ronald Rader - 1.55 billion
Wouter Deelder - 1.655 billion

House Judiciary Committee hearing on trade secret legislation, and the revolving door

On September 17, the House Judiciary marked up H.R. 5233, “The Trade Secret Protection Act of 2014.” The bill would create a civil right on action in federal courts for misappropriation of trade secrets, as defined in the bill. [Link to hearing, bill and transcript of markup].

Gilead's US patient access programs for Sovaldi

This is a note on Gilead run or funded programs that are available for patients residing in the United States.

Recently, Gilead's new hepatitis C drug, Sovaldi, has received much attention and criticism for its high price of $1000 a day.

Syndicate content